116 related articles for article (PubMed ID: 4036958)
1. Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia.
Alessandrino EP; Orlandi E; Brusamolino E; Lazzarino M; Bernasconi C
Am J Hematol; 1985 Oct; 20(2):191-3. PubMed ID: 4036958
[TBL] [Abstract][Full Text] [Related]
2. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
Winter JN; Variakojis D; Gaynor ER; Larson RA; Miller KB
Cancer; 1985 Aug; 56(3):443-9. PubMed ID: 3859362
[TBL] [Abstract][Full Text] [Related]
3. Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia.
Baccarani M; Zaccaria A; Bandini G; Cavazzini G; Fanin R; Tura S
Leuk Res; 1983; 7(4):539-45. PubMed ID: 6578393
[TBL] [Abstract][Full Text] [Related]
4. Low-dose Ara-C in myelodysplastic syndromes and acute nonlymphoid leukemia. Experience with seven patients.
Bruzzese L; Abbadessa A; Ottaiano L; Arcidiacone G
Haematol Blood Transfus; 1987; 30():315-21. PubMed ID: 3623239
[TBL] [Abstract][Full Text] [Related]
5. [The clinical effect of low-dose Ara-C in patients with refractory acute nonlymphocytic leukemia and myelodysplastic syndrome].
Yoshida M; Tsunoda S; Akutsu M; Furukawa Y; Takeda K; Akashi M; Komatsu N; Muroi K; Ikeda K; Ohsaka A
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1057-62. PubMed ID: 3566302
[TBL] [Abstract][Full Text] [Related]
6. [Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
Tsubaki K; Horiuchi A; Nagai K; Kanamaru A; Kohsaki M; Kitani T; Tagawa S; Masaoka T; Shibata H; Yasunaga K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):996-1003. PubMed ID: 3457553
[TBL] [Abstract][Full Text] [Related]
7. High-dose cytosine arabinoside in the treatment of preleukemic disorders: a leukemia intergroup study.
Preisler HD; Raza A; Barcos M; Azarnia N; Larson R; Browman G; Walker I; Grunwald H; D'Arrigo P; Stein A
Am J Hematol; 1986 Oct; 23(2):131-4. PubMed ID: 3529939
[TBL] [Abstract][Full Text] [Related]
8. High-dose cytosine arabinoside for acute nonlymphocytic leukemia.
Cantin G; Brennan JK
Am J Hematol; 1984 Jan; 16(1):59-66. PubMed ID: 6695910
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
[TBL] [Abstract][Full Text] [Related]
10. In vitro exposure of leukemic cells to low concentration Arabinosyl Cytosine: no evidence of differentiation inducing activity.
Motta MR; Baccarani M; Rizzi S; Fanin R; Fasola G; Poluzzi C; Tura S
Blut; 1987 May; 54(5):299-306. PubMed ID: 3567369
[TBL] [Abstract][Full Text] [Related]
11. Low-dose cytosine arabinoside for treating hypocellular acute leukemia in the elderly.
Kanamori H; Maruta A; Miyashita H; Harano H; Fukawa H; Matsuzaki M; Motomura S; Mohri H; Kodama F; Okubo T
Am J Hematol; 1992 Jan; 39(1):52-5. PubMed ID: 1536140
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of low-dose cytosine arabinoside.
Spriggs D; Griffin J; Wisch J; Kufe D
Blood; 1985 May; 65(5):1087-9. PubMed ID: 3995167
[TBL] [Abstract][Full Text] [Related]
13. Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine.
Larson RA; Wernli M; Le Beau MM; Daly KM; Pape LH; Rowley JD; Vardiman JW
Blood; 1988 Oct; 72(4):1333-9. PubMed ID: 3167210
[TBL] [Abstract][Full Text] [Related]
14. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukaemia.
Jensen MK; Ahlbom G
Scand J Haematol; 1985 Mar; 34(3):261-3. PubMed ID: 3992192
[TBL] [Abstract][Full Text] [Related]
15. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
[TBL] [Abstract][Full Text] [Related]
16. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
Cheson BD; Jasperse DM; Simon R; Friedman MA
J Clin Oncol; 1986 Dec; 4(12):1857-64. PubMed ID: 3537219
[TBL] [Abstract][Full Text] [Related]
17. In vitro correlates of low dose ara-C efficacy: clinical, cytogenetic, and bone marrow culture analysis.
Weisdorf DJ; Perri RT; Arthur DC; Machnicki JL; Oken MM; Miller WJ
Am J Hematol; 1987 May; 25(1):43-53. PubMed ID: 3578263
[TBL] [Abstract][Full Text] [Related]
18. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes.
Aul C; Schneider W
Cancer; 1989 Nov; 64(9):1812-8. PubMed ID: 2790694
[TBL] [Abstract][Full Text] [Related]
19. [Clinical effects of low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes].
Kanamori H; Maruta A; Fukawa H; Harano H; Kodama F; Miyashita H; Matsuzaki M; Noguchi T; Murata T; Hashimoto Y
Rinsho Ketsueki; 1991 Feb; 32(2):108-14. PubMed ID: 2027236
[TBL] [Abstract][Full Text] [Related]
20. Small-dose cytosine arabinoside in the treatment of elderly patients with acute leukemia and refractory anemia with excess of blast.
Satou Y; Kubota T; Yonekura S; Noguchi K; Oobayashi Y; Nagao T; Arimori S
Tokai J Exp Clin Med; 1986 Oct; 11(4):249-54. PubMed ID: 3617109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
